Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S.

The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on MedCity News.